To the Editor, We read with interest the work by Luo et al, 1 who described the use of tociluzumab in 15 patients with moderate‐to‐critical novel coronavirus infection (Coronavirus disease in 2019 [COVID‐19]) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). The development of cytokine release syndrome and T cell abnormalities plays a key role in the progression of COVID‐19. Under these circumstances, persistent viral stimulation leads to a significant increase in circulating cytokines such as interleukin (IL)‐6, IL‐10, and tumor necrosis factor α. The levels of these cytokines are negatively correlated with the absolute lymphocyte count, inducing the exhaustion and apoptosis of T cells which can trigger inflammatory damage to the organs. 2 It has been shown that IL‐6 plays a central role in the pathogenesis of SARS‐CoV‐2‐associated cytokine release syndrome and consequently Tocilizumab, a humanized monoclonal antibody against the IL‐6 receptor (IL‐6R) approved for the treatment of rheumatoid arthritis (RA) and giant cells arteritis, has gained interest as a potential treatment for COVID‐19 in clinical series. 3 A retrospective study on 21 patients with severe COVID‐19 showed that treatment with Tocilizumab (4‐8 mg/kg) improves oxygen saturation and computed tomography scan abnormalities, lymphocyte count, and normalizes C‐reactive protein (CRP) levels in most of the patients. 4 The randomized clinical trial investigating the safety and efficacy of Tocilizumab in COVID‐19 is still ongoing (ChiCTR2000029765). Based on Chinese data, on 17 March, the Italian Medicines Agency (AIFA) launched a prospective study on the use of Tocilizumab for COVID‐19. The rapid exhaustion of the drug led to the use of Sarilumab, another IL‐6R inhibitor employed in treatment of RA subcutaneously. AIFA has subsequently approved the Clinical Trial Protocol EFC16844 with reconstituted Sarilumab intravenously. All patients gave their written informed consent according to prospective nature of the study belong Declaration of Helsinki and Italian legislation (Authorization of the Privacy Guarantor No. 9, 12th December 2013). The Institutional Review Board, the Health Director of Hospital in Florence, reviewed and approved this research and the use of clinical and laboratory data of common clinical practice, in the respect of Privacy Law, for clinical and scientific studies and publications. We describe the clinical course of eight patients (mean age: 62 years; six men and two women) hospitalized in San Giovanni di Dio Hospital (Florence, Italy) for COVID‐19, confirmed by the SARS‐CoV2 reverse trascription polymerase chain reaction test. We added Sarilumab on their standard daily therapy with hydroxychloroquine 400 mg, azithromycin 500 mg, darunavir 800 mg, cobicistat 150 mg, enoxaparin 100 U/Kg. Sarilumab administration consisted in a dose of 400 mg equivalent to two single‐dose prefilled syringes, each containing 200mg Sarilumab in 1.14 mL solution (175mg/mL), added to 100mL 0.9% sodium chloride, for a 1‐hour intravenous infusion. The treatment was done after 24 hours from hospitalization (T0), and subsequently after 48 and 96 hours, at the dosage of 200 mg in intravenous infusion. Primary endopoint was the evaluation of respiratory function, described as at least a 30% reduction in oxygen requirement from baseline (meaning the ratio of O2 flow through the Venturi mask); an improvement of oxygenation expressed by an increased SpO2/FiO2 ratio (Horovitz index) by 50 or higher compared to nadir SpO2/FiO2 for at least 48 hours; improvement of ultrasound aspects with transition from moderate/severe B Wet Lung …